Abstract
Autoimmune hepatitis (AIH) is a common cause of acute and chronic hepatitis in childhood. Once the diagnosis is established, treatment with corticosteroid or corticosteroid and azathioprine is indicated. Most children with AIH respond to such therapy and experience remission from active disease. Eliminating drug therapy while maintaining remission is the ultimate goal of therapy. The optimal duration of therapy before drug elimination is unclear. Relapse rate is inversely related to therapy duration before drug withdrawal; thus, discontinuing immunosuppressive treatment is considered only after at least 1 to 2 years of complete remission. When applying a slow and systematic approach, many children with AIH can successfully be weaned off immunosuppression completely. Even patients presenting in acute liver failure may avoid liver transplantation with early medical therapy. In about 10% of patients, treatment fails, requiring alternative therapies and/or liver transplantation as liver disease progresses. Less than 10% of children with autoimmune hepatitis die during 10 years of follow-up.
Similar content being viewed by others
References and Recommended Reading
Czaja AJ: Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology 2008, 48:1540–1548.
Czaja AJ: Autoimmune liver disease. Curr Opin Gastroenterol 2006, 22:234–240.
Krawitt EL: Autoimmune hepatitis. N Engl J Med 2006, 354:54–66.
Mieli-Vergani G, Vergani D: Autoimmune paediatric liver disease. World J Gastroenterol 2008, 14:3360–3367.
Mieli-Vergani G, Vergani D: Autoimmune hepatitis. In: Liver Disease in Children, edn 3. Edited by Suchy FJ, Sokol RJ, Balistreri WF. New York: Cambridge University Press; 2007:447–458.
Kelly DA, ed: Diseases of the Liver and Biliary System in Children, edn 3. Hoboken, NJ: Wiley-Blackwell; 2008.
Murray KF, Hadzic N, Wirth S, et al.: Drug-related hepatotoxicity and acute liver failure. J Pediatr Gastroenterol Nutr 2008, 47:395–405.
Greene MT, Melin-Aldana H, Whitington PF: Outcome of pediatric autoimmune hepatitis [abstract S2080(576)]. Presented at Digestive Disease Week. San Diego, CA; May 17–22, 2008.
Seo S, Toutounjian R, Conrad A, et al.: Favorable outcomes of autoimmune hepatitis in a community clinic setting. J Gastroenterol Hepatol 2008, 23:1410–1414.
Al-Chalabi T, Underhill JA, Portmann BC, et al.: Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. J Hepatol 2008, 48:140–147.
Kerkar N, Annunziato RA, Foley L, et al.: Prospective analysis of nonadherence in autoimmune hepatitis: a common problem. J Pediatr Gastroenterol Nutr 2006, 43:629–634.
Czaja AJ: Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008, 6:379–388.
Montano-Loza AJ, Carpenter HA, Czaja AJ: Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol 2007, 102:1005–1012.
Verma S: In type 1 autoimmune hepatitis (AIH), should remission be redefined as normalization of transaminases? J Hepatol 2006, 44:819–820; auhor reply 820–821.
Alvarez F: Autoimmune hepatitis and primary sclerosing cholangitis. Clin Liver Dis 2006, 10:89–107, vi.
Zandieh I, Krygier D, Wong V, et al.: The use of budesonide in the treatment of autoimmune hepatitis in Canada. Can J Gastroenterol 2008, 22:388–392.
Cuarterolo M, Ciocca M, Velasco CC, et al.: Follow-up of children with autoimmune hepatitis treated with cyclosporine. J Pediatr Gastroenterol Nutr 2006, 43:635–639.
Larsen FS, Vainer B, Eefsen M, et al.: Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 2007, 13:3232–3236.
Ichai P, Duclos-Vallee JC, Guettier C, et al.: Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007, 13:996–1003.
Montano-Loza AJ, Carpenter HA, Czaja AJ: Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am J Gastroenterol 2008, 103:1944–1951.
Miyake Y, Iwasaki Y, Terada R, et al.: Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis. Aliment Pharmacol Ther 2006, 24:1197–1205.
Khalaf H, Mourad W, El-Sheikh Y, et al.: Liver transplantation for autoimmune hepatitis: a single-center experience. Transplant Proc 2007, 39:1166–1170.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Greene, M.T., Whitington, P.F. Outcomes in pediatric autoimmune hepatitis. Curr Gastroenterol Rep 11, 248–251 (2009). https://doi.org/10.1007/s11894-009-0038-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11894-009-0038-y